Nan Lan
Impact in
- Physiology top 5%
- Adenosine and Purinergic Signaling
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Surgery 5
- Esophageal and GI Pathology 3
- Co-authors
- Ping Lan (6 shared papers)Xianrui Wu (6 shared papers)Xiaosheng He (3 shared papers)Yifeng Zou (2 shared papers)Lei Lian (2 shared papers)Yang Zeng (2 shared papers)Xiaojian Wu (2 shared papers)Tuo Hu (2 shared papers)
- Journals
- Journal of Gastrointestinal Surgery (2 papers)Molecular Therapy (1 paper)Gastrointestinal Endoscopy (1 paper)Diseases of the Colon & Rectum (1 paper)Journal of Surgical Oncology (1 paper)
- Partner nations
- ChinaUnited StatesSaudi Arabia
In The Last Decade
Nan Lan
14 papers receiving 341 citations
Peers
Comparison fields: 5 of 68
- Physiology 99
- Cancer Research 115
- Immunology 94
- Oncology 120
- Molecular Biology 170
Countries citing papers authored by Nan Lan
This map shows the geographic impact of Nan Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Lan more than expected).
Fields of papers citing papers by Nan Lan
This network shows the impact of papers produced by Nan Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Lan. The network helps show where Nan Lan may publish in the future.
Co-authors
The 25 scholars most cited alongside Nan Lan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 148 | |
| 2 | 2019 | 115 | |
| 3 | 2012 | 25 | |
| 4 | 2021 | 10 | |
| 5 | 2020 | 8 | |
| 6 | 2022 | 7 | |
| 7 | 2007 | 7 | |
| 8 | 2016 | 6 | |
| 9 | 2020 | 6 | |
| 10 | 2018 | 5 | |
| 11 | 2020 | 4 | |
| 12 | 2020 | 3 | |
| 13 | 2013 | 2 | |
| 14 | [The effect of Rac1 siRNA on the biological behaviors of gastrointestinal cancer cells]. | 2009 | 1 |
| 15 | 2025 | 0 | |
| 16 | 2019 | 0 | |
| 17 | 2016 | 0 |
About Nan Lan
Nan Lan is a scholar working on Surgery, Molecular Biology, Pulmonary and Respiratory Medicine, Oncology and Immunology, having authored 17 papers that have together received 347 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (3 papers), Esophageal and GI Pathology (3 papers), COVID-19 and healthcare impacts (3 papers), Infection Control and Ventilation (2 papers), MicroRNA in disease regulation (2 papers), Gastric Cancer Management and Outcomes (2 papers), Adenosine and Purinergic Signaling (2 papers) and Inflammatory Bowel Disease (2 papers). The work is most often cited by research in Physiology (99 citations), Cancer Research (115 citations), Immunology (94 citations), Oncology (120 citations) and Molecular Biology (170 citations). Nan Lan has collaborated with scholars based in China, United States and Saudi Arabia. Frequent co-authors include Ping Lan, Xianrui Wu, Xiaosheng He, Yifeng Zou, Lei Lian, Yang Zeng, Xiaojian Wu, Tuo Hu, Chi Zhou and Feng-Wei Wang. Their work appears in journals such as Journal of Gastrointestinal Surgery, Molecular Therapy, Gastrointestinal Endoscopy, Diseases of the Colon & Rectum and Journal of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.